Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin ®) in animals and humans

Xenobiotica

Volumn 34, Issue 6, 2004, Pages 591-606

  Wu, W N ^a   McKown, L A ^a   Moyer, M D ^a   Cheung, W ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Johnson Johnson Pharmaceutical R D   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLADRIBINE; CLADRIBINE GLUCURONIDE; CLADRIBINE SULFATE; DRUG METABOLITE; GLUCURONIDE; IMMUNOSUPPRESSIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG OXIDATION; DRUG RESEARCH; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FECES ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN VERSUS ANIMAL COMPARISON; MALE; MONKEY; MOUSE; NONHUMAN; RAT; THIN LAYER CHROMATOGRAPHY; URINALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLADRIBINE; FEMALE; HAPLORHINI; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MASS SPECTROMETRY; MICE; MICROSOMES, LIVER; MOLECULAR STRUCTURE;

ANIMALIA;

EID: 3242769163     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250410001713140     Document Type: Article

References (19)

1. BENTLER, E., 1992, Cladribine (2-chlorodeoxyadenosine). Lancet, 340, 952-956.
2. BENTLER, E., KOZIOL, J., McMILLAN, R., SIPE, J. C., ROMINE, J. S. and CARRERA, C. J., 1994, Marrow suppression produced by repeated dose of cladribine. Acta Haematologica, 91, 10-15.
3. BENTLER, E., PIRO, L. D. and SAVAN, A., 1991, 2-Chloro-2Ç- deoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leukemia and Lymphoma, 5, 1-8.
4. CARSON, D. A., KAYE, J. and SEEGMILLER, J. E., 1977, Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency, possible role of nucleoside kinase (s). Proceedings of the National Academy of Sciences, USA, 74, 5677-5681.
5. CARSON, D. A., WASSON, D. B. and BENTLER, B, 1984, Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proceedings of the National Academy of Sciences, USA, 81, 2232-2236.
6. CARSON, D. A., WASSON, D. B., ESPARZA, L. M., CARRERA, C. J., KIPPS, T. J. and COTTAM, H. B., 1992, Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proceedings of the National Academy of Sciences, USA, 89, 1970-1974.
7. CARSON, D. A., WASSON, D. B., TEATLE, R. and YU, A., 1983, Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytee. Blood, 62, 737-743.
8. CHABNER, B. A., RYAN, D. P., PAZ-ARES, L., GARCIA-CARBONERO, R. and CALABRESI, P., 2001, Antineoplastic agents. In J. G. Hardman, L. E. Limbird and A. G. Gilman (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn (New York: McGraw-Hill), pp. 1389-1459.
9. DE MIRANDA, P., BURNETT, T. and GOOD, S. S., 1990, Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metabolism and Disposition, 18, 315-320.
10. LILIEMARK, J. and JULIUSSON, G., 1991, On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Research, 51, 5570-5572.
11. LILIEMARK, J., ALBERTIONI, F., HASSAN, M. and JULIUSSON, G., 1992, On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. Journal of Clinical Oncology, 10, 1514-1518.
12. MOYER, M. D., JOHANNSEN, T. and STUBBS, R. J., 1998. Determination of 2-chlorodeoxyadenosine (cladribine, 2-CdA) in human plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Journal of Pharmacological and Biomedical Analysis, 17, 45-51.
13. RICE, G. P., FILIPPI, M. and COMI, G., 2000. Cladribine and progressive MS clinical and MRI outcomes of a multicenter controlled trial. Neurology, 54, 1145-1155.
14. RISCOE, M. K., BROUNS, M. C. and FITCHEN, J. H., 1989. Purine metabolism is a target for leukemia chemotherapy. Blood Reviews, 3, 162-173.
15. SAVEN, A., CHEUNG, W., SMITH, I., MOVER, M., JOHANNSEN, T., ROSE, E., GLLARD, R., KOSTY, M., MILLER, W. and PIRO, L., 1996, Pharmacokinetics study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy, Journal of Clinical Oncology, 14, 978-993.
16. SAVEN, A. and PIRO, L. D., 1992, Treatment of hairy cell leukemia, Blood, 79, 1111-1120.
17. SETO, S., CARRERA, C. J., KUBOTA, M., WASSON, D. B. and CARSON, D. A., 1985, Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. Journal of Clinical Investigation, 75, 377-378.
18. SIPE, J. C., ROMINE, J. S., KOZIOL, J. A., MCMILLAN, R., ZYROFF, J. and BENTLER, E., 1994, Cladribine in treatment of chronic progressive multiple sclerosis. Lancet, 344, 9-13.
19. WU, W. N., MCKOWN, L. A. MOYER, M. D. and CHEUNG, W., 1999, The in vivo metabolism of cladribine in the mouse, monkey and human. ISSX Proceedings, 14, 91 (abst.comma; 7th European ISSX Meeting).